Literature DB >> 15913914

Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.

Jonathan B Ashman1, Michael J Zelefsky, Margie S Hunt, Steven A Leibel, Zvi Fuks.   

Abstract

PURPOSE: To investigate the correlations between observed clinical morbidity and dosimetric parameters for whole pelvic radiotherapy (WPRT) for prostate cancer using either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT). METHODS AND MATERIALS: Between December 1996 and January 2002, 27 patients with prostate adenocarcinoma were treated with conformal WPRT as part of their definitive treatment. WPRT was delivered with 3D-CRT in 14 patients and with IMRT in 13 patients. For each of the patients treated with IMRT, optimized conventional two-dimensional (2D) and 3D-CRT plans were retrospectively generated for the whole pelvic phase of the treatment. Dose-volume histograms for the bowel, bladder, and rectum were compared for the three techniques. Acute toxicities were evaluated for all 27 patients, and late toxicities were evaluated for 25 patients with sufficient follow-up. Toxicities were scored according to the Radiation Therapy Oncology Group morbidity grading scales. Median follow-up was 30 months.
RESULTS: Three-dimensional-CRT resulted in a 40% relative reduction (p < 0.001) in the volume of bowel receiving 45 Gy compared with 2D, and IMRT provided a further 60% reduction relative to 3D-CRT (p < 0.001). Compared with either 2D or 3D-CRT, IMRT reduced the volume of rectum receiving 45 Gy by 90% (p < 0.001). Overall, 9 patients (33%) experienced acute Grade 2 gastrointestinal (GI) toxicity, and only 1 of these patients was treated with IMRT. Antidiarrhea medication was required for 6 patients (22%). However, 5 of these 6 patients also received chemotherapy, and none were treated with IMRT. No Grade 3 or higher acute or late GI toxicities were observed. No cases of late radiation enteritis were observed. Acute and late genitourinary toxicity did not appear significantly increased by the addition of conformal WPRT.
CONCLUSIONS: Compared to conventional 2D planning, conformal planning for WPRT resulted in significant reductions in the doses delivered to the bowel, rectum, and bladder. IMRT was superior to 3D-CRT in limiting the volume of bowel and rectum within high-dose regions. These dosimetric findings correlated with low rates of acute and late GI morbidity.

Entities:  

Mesh:

Year:  2005        PMID: 15913914     DOI: 10.1016/j.ijrobp.2005.02.050

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  30 in total

1.  [Radiotherapy in prostate cancer].

Authors:  U Ganswindt; C Belka
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

2.  Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value >40 ng/ml.

Authors:  Jiri Kubeš; Cvek Jakub; Vondráček Vladimir; Dvořák Jan; Argalacsová Sona; Navrátil Matej; Buřil Jan
Journal:  Rep Pract Oncol Radiother       Date:  2012-02-09

3.  No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy.

Authors:  Barbara A Jereczek-Fossa; Delia Ciardo; Silvia Ferrario; Piero Fossati; Giuseppe Fanetti; Dario Zerini; Davide Zannoni; Cristiana Fodor; Marianna A Gerardi; Alessia Surgo; Matteo Muto; Raffaella Cambria; Ottavio De Cobelli; Roberto Orecchia
Journal:  Br J Radiol       Date:  2016-04-25       Impact factor: 3.039

4.  Radiobiological comparison of two radiotherapy treatment techniques for high-risk prostate cancer.

Authors:  Trinitat García Hernández; Aurora Vicedo González; Jorge Pastor Peidro; Juan V Roselló Ferrando; Luis Brualla González; Domingo Granero Cabañero; José López Torrecilla
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-08

5.  Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse.

Authors:  Anja M Weidner; Emile N J Th van Lin; Dietmar J Dinter; Tom Rozema; Stefan O Schoenberg; Frederik Wenz; Jelle O Barentsz; Frank Lohr
Journal:  Strahlenther Onkol       Date:  2011-02-21       Impact factor: 3.621

6.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

7.  Acute gastrointestinal toxicity and tumor response with preoperative intensity modulated radiation therapy for rectal cancer.

Authors:  Arti Parekh; Minh Tam Truong; Itai Pashtan; Muhammad M Qureshi; Neil E Martin; Omer Nawaz; Sandra Cerda; John Willins; Kevan L Hartshorn; Lisa A Kachnic
Journal:  Gastrointest Cancer Res       Date:  2013-09

8.  Prostate image-guided radiotherapy by megavolt cone-beam CT.

Authors:  Sergio Zucca; Barbara Carau; Ignazio Solla; Elisabetta Garibaldi; Paolo Farace; Giancarlo Lay; Gianfranco Meleddu; Pietro Gabriele
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

Review 9.  Intensity-modulated radiation therapy for gastrointestinal tumors.

Authors:  Jeffrey J Meyer; Brian G Czito; Christopher G Willett
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

Review 10.  Optimal treatment strategies for anal cancer.

Authors:  Shahab Ahmed; Cathy Eng
Journal:  Curr Treat Options Oncol       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.